Walgreens settles fraud cases for $269M

Walgreens Boots Alliance has settled two fraud cases with the Department of Justice, shelling out $269.2 million. In both cases, which arose from whistleblowers, Walgreens admitted and accepted responsibility for conduct alleged by the government in its complaint under the False Claims Act.

The first settlement of $209.2 million resolves allegations that the company improperly billed Medicare, Medicaid and other federal healthcare programs for hundreds of thousands of insulin pens it dispensed to program beneficiaries who did not need them.

The company allegedly configured its pharmacy management system to prevent pharmacists from dispensing fewer than a box full of five insulin pens, even in cases when patients did not need that much of the medicine. Walgreens also evaded government limits on the daily supply of insulin by falsely stating the supplies did not go over the limit in its reimbursement claims.

“As a result, federal healthcare programs paid WALGREENS millions of dollars for insulin that many beneficiaries did not actually need, and substantial quantities of valuable medication were wasted,” the DOJ stated.

Walgreens will pay $168 million to the United States and $41.2 million to state governments.

“Walgreens engaged in practices that undermined the integrity of the Medicare and Medicaid programs, compromised patient care, and wasted taxpayer dollars,” HHS-OIG Special Agent in Charge Scott J. Lampert said in a statement. “Along with our law enforcement partners, HHS-OIG will continue to protect the individuals that depend on federally funded health care programs, and ensure that companies that do business with those programs do so in an honest fashion.”

Walgreens also agreed to pay $60 million to settled allegations it knowingly overcharged government healthcare plans for prescription drugs. The retail pharmacy allegedly offered discounted prices to the general public, including government healthcare program beneficiaries, but charged government programs significantly higher amounts.

The settlement is the largest of its kind against a retail pharmacy under the qui tam whistleblower provisions of the False Claims Act, according to Stein Mitchell Beato & Missner LLP, which represented the whistleblower in a lawsuit against Walgreens.

Walgreens will pay $32 million to the United States and $28 million to state governments.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.